Literature DB >> 2143137

Comparative effects of enoximone and theophylline on plasma catecholamines and haemodynamics in cardiosurgical patients.

J Boldt1, H A Adams, B Zickmann, D Kling, G Hempelmann.   

Abstract

The release of endogenous catecholamines in aorto-coronary bypass graft patients receiving either 0.5 mg/kg enoximone (n = 10), 4.0 mg/kg theophylline (n = 10) or saline solution (control, n = 10) has been studied, as well as certain haemodynamic parameters. Adrenaline (A) and noradrenaline (NA) concentrations were not significantly changed by the administration of enoximone. Theophylline caused a small increase in NA (+40% in the 1st min) and a marked increase in A (approximately +7000% in the 1st min), which still remained elevated at the end of the investigation period (+220% in the 30th min). The major haemodynamic effects of enoximone were a significant increase in cardiac index (CI; +35%) and a decrease in pulmonary capillary wedge pressure (PCWP; -27%), pulmonary artery pressure (PAP; -21%), RVEDV and RVESV, while the heart rate (HR) remained almost unchanged. The dominant haemodynamic effects of theophylline were an increase in HR (+26%; arrhythmia in 3 patients), PAP (+22%), and RVEDV (+19%), while RVESV (+26%), MAP (-16%), CI (-14%), and RVEF (-15%) fell significantly. It is concluded that the haemodynamic actions of enoximone are not mediated by catecholamine release, whereas the adverse cardiovascular effects of theophylline might partly be explained by the significant increase in plasma adrenaline.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143137     DOI: 10.1007/bf02336679

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  [Endocrine stress response in halothane, enflurane and isoflurane anesthesia in surgical interventions].

Authors:  H A Adams; W Russ; M Leisin; U Börner; H Gips; G Hempelmann
Journal:  Anaesthesist       Date:  1987-04       Impact factor: 1.041

2.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

3.  Effect of caffeine and theophylline on peripheral catecholamines.

Authors:  B A Berkowitz; S Spector
Journal:  Eur J Pharmacol       Date:  1971-01       Impact factor: 4.432

Review 4.  Phosphodiesterase inhibition and theophylline.

Authors:  H Bergstrand
Journal:  Eur J Respir Dis Suppl       Date:  1980

Review 5.  Role of cyclic nucleotides in heart metabolism.

Authors:  L H Opie
Journal:  Cardiovasc Res       Date:  1982-09       Impact factor: 10.787

6.  Measurement of ejection fraction by thermal dilution techniques.

Authors:  H R Kay; M Afshari; P Barash; W Webler; A Iskandrian; C Bemis; A H Hakki; E D Mundth
Journal:  J Surg Res       Date:  1983-04       Impact factor: 2.192

7.  Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure.

Authors:  B F Uretsky; T Generalovich; P S Reddy; R Salerni; A M Valdes; R B Spangenberg; J F Lang; R A Okerholm
Journal:  Am J Cardiol       Date:  1984-08-01       Impact factor: 2.778

8.  Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.

Authors:  W S Colucci; R F Wright; B E Jaski; M A Fifer; E Braunwald
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

9.  Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite.

Authors:  R A Okerholm; K Y Chan; J F Lang; G A Thompson; S J Ruberg
Journal:  Am J Cardiol       Date:  1987-08-14       Impact factor: 2.778

10.  Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man.

Authors:  R E Vestal; C E Eiriksson; B Musser; L K Ozaki; J B Halter
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.